← Back to screener

BridgeBio Oncology Therapeutics, Inc. BBOT

Rank #1814 · Nasdaq · $0.2B market cap
Audited by Deloitte & Touche, LLP, no going-concern flag in the latest filing.
Score
41.6
P/E
-2.8
P/B
-1.81
ROE
64.2%
Op. Margin
–%
Debt Ratio
-17%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -2.8x, P/B -1.81x. Ranks in the top 98% of the universe.

Profitability ★★★★★
Excellent

ROE 64.2%. Ranks in the top 6% of the universe.

Safety ★★★★★
Excellent

Debt ratio -17%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024–$-0.0B$-0.0B$-0.0B–-1812
2025–$-0.1B$-0.1B$-0.1B–-17

← See the full screener